Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at Siemens Health Diagnostics,...
Ceres Nanosciences Establishes Sixteen Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative
MANASSAS, Va., April 6, 2022 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of six new wastewater-based epidemiology centers of excellence. The new centers add to the nine existing centers of excellence previously announced in...
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that the Investigational New Drug (IND) application of its second fatty acid synthase (FASN) inhibitor ASC60 for treatment of advanced solid tumors has been approved by China National Medical Products Administration. ASC60 IND approval further strengthens Ascletis' oncology pipeline. Many...
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced that the poster presentation on HBM9027, a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for...
Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US.
STOCKHOLM, April 6, 2022 /PRNewswire/ -- Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led by European life science venture fund Hadean Ventures and joined by Scale Capital and Bonit Capital. Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies seeking to develop and...
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022. MBS funding will cover the initial staging of intermediate to...
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed...
SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the National Medical Products Administration (NMPA) has approved Pemazyre® (pemigatinib) for the treatment of adults with locally advanced or metastatic...
VISTA Eye Specialist (VISTA) introduces cutting-edge Swiss Technology for Cataract Surgery, giving patients a simple, fast and safe procedure.
PETALING JAYA, Malaysia, April 6, 2022 /PRNewswire/ -- VISTA is always looking to provide the latest technology available for Cataract patients - making the surgery simpler and improve the result, safety and comfort - not just for the patient but also the surgeon. Having Robotic Computer-aided technology that automates processes, takes away the constant demands of a surgeon's attention...
Cambridge Nutranostics has developed a point-of-care prototype of OCCL test for testing blood plasma oxygen to monitor health in post stroke and TIA patients for dementia prevention
CAMBRIDGE, England, April 6, 2022 /PRNewswire/ -- Cambridge Nutranostics Ltd, CNL, http://occltest.com has begun validation in clinic of its first test prototype to assess and monitor plasma oxygen, the part of the total blood O2, which can cross the capillary wall and deliver this essential gas for tissue cell respiration. Medical researchers from Cambridge University, Papworth Hospital and led...
Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02). Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors. Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms. The Phase III multi-regional clinical trial...
